Dividend compounder review

HALO

Halozyme Therapeutics Inc · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score59.00/100
Confidence82.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 14.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 23.5 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 8.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 13.5 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$316.9M
Free Cash Flow$356.8M
FCF Covers DividendUnknown
Debt / Equity9.91
P/E24.4
Revenue Growth 5Y39.2%
Net Margin23.1%
ROE99.4%
Price vs Trend1.5%
3Y Return103.6%
5Y Return54.0%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Debt to equity is elevated at 9.91.
Dividend diary

Activity record

HALO dividend review warning Warning · Warning

Debt to equity is elevated at 9.91.